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Abstract A novel member of the human UDP-N-acetyl-D-
galactosamine :polypeptide N-acetylgalactosaminyltransferase
gene family, designated GalNAc-T7, was cloned and expressed.
GalNAc-T7 exhibited different properties compared to other
characterized members of this gene family, in showing apparent
exclusive specificity for partially GalNAc-glycosylated acceptor
substrates. GalNAc-T7 showed no activity with a large panel of
non-glycosylated peptides, but was selectively activated by
partial GalNAc glycosylation of peptide substrates derived from
the tandem repeats of human MUC2 and rat submaxillary gland
mucin. The function of GalNAc-T7 is suggested to be as a follow-
up enzyme in the initiation step of O-glycosylation.
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1. Introduction
The initiation step of mucin-type O-linked protein glycosyl-
ation is controlled by a family of UDP-GalNAc: polypeptide
N-acetylgalactosaminyltransferases (GalNAc-transferases)
(EC 2.4.1.41), which transfer N-acetylgalactosamine to serine
and threonine amino acid residues [1]. Six members of the
mammalian GalNAc-transferase family have been reported
[2^8] and additional members of the gene family have been
identi¢ed (E.P. Bennett and H. Clausen, unpublished). Anal-
ysis of the in vitro kinetic properties of recombinant forms of
these enzymes have revealed several characteristics : (a) the
transferases show acceptor substrate speci¢cities that di¡er
but with some overlap, especially for substrates on mucin
tandem repeats [4,5,7,9] ; (b) the order in which individual
sites in multiple site acceptor peptides are glycosylated by
di¡erent enzymes di¡ers markedly [9,10] and (c) the catalytic
action of multiple GalNAc-transferases may be cooperative,
as evidenced by the ¢nding that glycosylation of some accept-
or sites in the MUC1 tandem repeat by GalNAc-T4 requires
prior glycosylation by GalNAc-transferases with di¡erent sub-
strate speci¢cities [5]. The latter phenomenon is poorly under-
stood. Preceding GalNAc glycosylation at selected sites in an
acceptor peptide may induce conformational changes that are
required for some GalNAc-transferases to function. Alterna-
tively, the attached GalNAc residue(s) may be directly in-
volved in recognition of the acceptor substrate site by some
GalNAc-transferases.
Here, we report on a novel GalNAc-transferase, designated
GalNAc-T7, that exhibits a similar preference for GalNAc-
glycosylated substrates as previously found for GalNAc-T4
with peptide substrates derived from the tandem repeat of
MUC1 [5]. The kinetic properties of GalNAc-T7 were unique
in that its GalNAc glycopeptide substrate speci¢city was dif-
ferent from that of GalNAc-T4, and in contrast to GalNAc-
T4, GalNAc-T7 would only catalyze glycosylation of acceptor
substrates with prior glycosylation.
2. Materials and methods
2.1. Identi¢cation and cloning of cDNA for GalNAc-T7
tBLASTn analysis of expressed sequence tags (EST) sequence in-
formation at The National Center for Biotechnology Information was
used to identify a putative novel GalNAc-transferase isoform, desig-
nated GalNAc-T7. One EST clone (EST181335) contained part of an
open reading frame with sequence similarity to GalNAc-transferases.
5P sequence was obtained by 5Prapid ampli¢cation of cDNA ends
(RACE) with a Vgt10 cDNA library from the gastric carcinoma
cell line MKN45 [3]. Two subsequent 5PRACE reactions with
primers EBHC 1101 (5P-TAAGCGGCACAGTGCAAATGG-3P)
and EBHC1106 (5P-GAGATCATGTCACTTGCCACC-3P) generated
a total of 560 bp sequence 5P of the EST clone. Further 5P-RACE
experiments failed, and residual 5P coding sequence (110 bp) was
obtained by sequencing on genomic clone BACH-6dl-18083 (BAC-
18083). This clone was isolated by use of the primer pair
EBHC1106/1113 (5P-CGCAGCGGGCGGCCGCCCTGGAGAGAA-
AGCCAAGC-3P) using Genome Systems BAC Human library screen-
ing services.
2.2. Expression of GalNAc-T7 in insect cells
An expression construct of a secreted form of GalNAc-T7,
pAcGP67-GalNAc-T7-sol, was prepared by RT-PCR using primers
EBHC1122 (5P- CGCAGCGGGCGGCCGCTGAGCAGGATGAG-
GGAAGAC-3P) and EBHC1116 (5P- CGCAGCGGGCGGCCG-
CTCTCTAAACACTATGGATGTTATTC-3P) with NotI overhangs
and the product was cloned into the vector pAcGP67 (Pharmingen)
and fully sequenced. RNA from MKN45 was used as template for
RT-PCR. Control expression constructs included pAcGP67-GalNAc-
T4-sol [5] and other GalNAc-transferases and irrelevant genes. Co-
transfection of Sf9 cells with pAcGP67-GalNAc-T7-sol and Baculo-
Gold DNA was performed as previously described [4].
2.3. Northern hybridization
Multiple tissue Northern (MTNIII) blot was obtained from Clon-
tech. The soluble expression construct was used as the GalNAc-T7
probe. The probe was random-primed and labelled using [K-32P]dCTP
(Amersham) and Oligo labelling kit (Pharmacia). Blots were probed
as described previously [4] and washed 5Uat 42‡C with 2USSC, 0.1%
SDS, once with 0.5USSC, 0.1% SDS, and once at 55‡C with
0.1USSC, 0.1% SDS, in a mini-hybridization oven (HYBAID).
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2.4. Polypeptide GalNAc-transferase assays
Standard reaction mixtures (50 Wl ¢nal volume) contained 25 mM
cacodylate (pH 7.4), 10 mM MnCl2, 0.25% Triton X-100, 200 WM
UDP-[14C]GalNAc (2000 cpm/nmol)(Amersham), and 200^500 WM
acceptor peptides. Products were quanti¢ed by scintillation counting
after chromatography on Dowex-1, octadecyl silica cartridges (Baker-
bond) or HPLC (PC3.2/3 or mRPC C2/C18 SC2.1/10 Pharmacia,
Smart System). The panel of acceptor peptides tested included
TAP25 (TAPPAHGVTSAPDTRPAPGSTAPPA; human MUC1 tan-
dem repeat [11]), Muc2 (PTTTPISTTTMVTPTPTPTC; human intes-
tinal mucin MUC2 [12]), Muc5AC (Ac-SAPTTSTTSAPT; human
respiratory gland mucin MUC5AC [13]), Muc7 (Ac-CPPTPSATT-
PAPPSSSAPPETTAA, human salivary gland mucin MUC7 [14]),
EA2 (DSTTPAPTTK; rat submandibular gland mucin [15]),
VTHPGY (Ac-PFVTHPGYD; human ¢bronectin [16]), zonadhesin
(PTERTTTPTKRTTTPTIR; human zonadhesin [17]), OSM frag-
ment (LSESTTQLPGGGPGCA; ovine submaxillary mucin [18]),
hCG-L (PRFQDSSSSKAPPPLPSPSRLPG; human chorionic gona-
dotropin L-subunit [19]), and PSGL-1b (Ac-QATEYEYLDYDFLPE-
TEPPEM; N-terminus of human P-selectin ligand-1 [20]). GalNAc-
glycopeptides of the peptides of TAP25, Muc2, Muc5AC, Muc7 and
EA2 were produced using cold UDP-GalNAc and puri¢ed human
recombinant GalNAc-T2 (Table 1). Di¡erent GalNAc-glycoforms of
EA2 were produced by limiting the ratio of UDP-GalNAc to 2^5 mol
per mol of acceptor peptide. Glycopeptides were puri¢ed on Supel-
clean LC-18 columns (1 ml, Supelco) and the number of GalNAc
residues incorporated evaluated by matrix-assisted laser desorption/
ionization mass spectrometry time-of-£ight (MALDI-TOF). Spectra
were acquired on a Voyager-DE mass spectrometer (Perseptive Bio-
system) equipped with delay extraction. The enzyme sources used
were semipuri¢ed as previously described by successive sequential
ion-exchange chromatographies on Amberlite (IRA95, Sigma) or
DEAE Sephacel (Amersham Pharmacia Biotech) and S-Sepharose
Fast Flow (Amersham Pharmacia Biotech) [5,9]. Secreted GalNAc-
T4 was obtained from a stably transfected CHO line (CHO/GalNAc-
T4/21A) [5] grown in roller bottles in HAMS F12 supplemented with
10% fetal bovine serum. Secreted GalNAc-T7 was obtained from in-
fected High Five cells grown in serum-free medium (Invitrogen) in
upright roller bottles shaken 140 rpm in waterbaths at 27‡C. The
activities found with puri¢ed GalNAc-T4 expressed in CHO cells
deviated slightly from those reported previously for GalNAc-T4 ex-
pressed in insect cells [5,8]. These di¡erences may in part be due to
higher levels of contaminating endogenous GalNAc-transferase activ-
ities in the medium of insect cells.
3. Results
3.1. Cloning of GalNAc-T7
GalNAc-T7 was identi¢ed by analysis of the EST database
[8], and the human sequence obtained by a combination of
PCR-based cDNA cloning and by genomic cloning. The com-
posite sequence contained an open reading frame of 1974 bp,
which predicted a type II transmembrane protein with a hy-
drophobic signal anchor sequence in residues 10^24 (Fig. 1).
The 3PUTR is almost 2.2 kb and contains a consensus poly-
adenylation signal. Multiple human ESTs are derived from
the 3PUTR, while only two 5PESTs contain the coding se-
quence of GalNAc-T7. The nucleotide sequence reported in
this paper has been submitted to the GenBank/EMBL data
bank with accession number AJ002744. GalNAc-T7 had no
consensus N-linked glycosylation sites. Multiple sequence
alignment analysis of the seven human GalNAc-transferases
cloned and expressed so far (Fig. 1), shows that GalNAc-T7
share common sequence motifs with GalNAc-transferases.
GalNAc-T7 is distinct in sequence outside these shared motifs
from other members of this gene family, indicating that this
gene does not ¢t within any known subfamilies of other iden-
ti¢ed genes [8]. This is further supported by preliminary anal-
ysis of the genomic organization of the gene for GalNAc-T7,
designated GALNT7, (E.P. Bennett, unpublished), which is
di¡erent from other characterized GalNAc-transferases
[8,21]. GALNT7 was localized to chromosome 4q31.1 between
D4S1566 and D4S1596 at 157.9-169.1 cM by 3PEST mapping
data (stSG31267) as reported under Hs.62817 in Unigene. The
3PUTR sequence identi¢ed by sequencing on genomic clone
BACH-6dl-18083 was identical to the sequence of this Uni-
gene cluster.
Northern analysis revealed high expression of a 4.2 kb tran-
script in most of the human organs analyzed suggesting a
quite ubiquitous expression pattern (Fig. 2). The 3P and
5PESTs derived from GalNAc-T7 originated from a large
variety of di¡erent organs including pancreas, uterus, retina,
kidney, small intestine, omentum, stomach and CNS. Murine
ESTs derived from the putative GalNAc-T7 orthologue
showed a similar broad pattern of expression. There were
additional 5PESTs covering the coding sequence.
3.2. Kinetic properties of GalNAc-T7
A secreted construct of GalNAc-T7 was expressed in insect
cells and no activity was demonstrated in initial assays with a
large panel of peptide substrates as described in the Section 2
(not shown). As shown in Table 1, GalNAc-T7 had catalytic
activity with selected GalNAc-glycosylated peptides derived
from mucin tandem repeats. Catalytic activity with Gal-
NAc1ÿ2Muc2 and GalNAc1ÿ2EA2 is 10-fold greater than
the non-glycosylated peptide substrate. GalNAc-T7 showed
no activity with the GalNAc glycosylated Muc1 substrate.
The activity of GalNAc-T7 with glycopeptides was di¡erent
from GalNAc-T4.
Previously, we found that GalNAc-T4 had unique activity
with two sites in the tandem repeat of MUC1 if the three
other sites in the repeat were GalNAc glycosylated using the
glycopeptide, GalNAc4TAP24 (TAPPAHGVTSAPDTR-
PAPGSTAPP, GalNAc attachment sites underlined) [5]. The
Table 1
Substrate speci¢citiesa of semi-puri¢ed recombinant GalNAc-T4 and -T7
TAP24 MUC2 MUC5AC MUC7 EA2
3b +c 3 + 3 + 3 + 3 +
GalNAc-T4 0.4 1.8 3.33 16.1 0.7 5.3 2.9 2.0 7.4 1.0
GalNAc-T7 0 0 0 10.3 0.1 0.3 0 0.4 0.3 4.2
GalNAc4TAP24 is terminal glycosylated with GalNAc-T2 (4 mol GalNAc/mol peptide). Other GalNAc-glycopeptides are glycosylated with
GalNAc-T2 using limitation in donor substrate (2 mol UDP-GalNAc/mol peptide) as described under Section 2. Mass spectrometric analysis of
the used glycopeptides indicates that 1^2 mol was incorporated (not shown).
amilliunits/ml, 1 unit of enzyme is de¢ned as the amount of enzyme that transfer 1 Wmol GalNAc in 1 min using the standard reaction mix-
ture.
b3, non-glycosylated peptide substrates.
c +, GalNAc glycosylated peptide substrates, glycosylated using human GalNAc-T2.
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two sites, S in -VTSA- and T in -PDTR-, are not utilized by
other characterized GalNAc-transferases, whereas GalNAc-
T1, -T2 and -T3 can transfer to the three sites, T in -VTSA-
and ST in -GSTA- [9]. GalNAc-T4 also utilize several non-
glycosylated peptide substrates, including those derived from
the tandem repeats of MUC2, MUC7 and a rat submandib-
ular mucin (peptide from latter designated EA2) [5]. Here, we
found that catalytic activity of GalNAc-T4 with the Muc2
peptide was enhanced ¢ve-fold by prior incorporation of 1^
2 mol of GalNAc by GalNAc-T2 (Table 1). Similarly, an
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eight-fold enhancement was observed for the Muc5AC pep-
tide with the GalNAc-glycoform. In contrast, GalNAc-glyco-
sylation had no e¡ect on glycosylation of the Muc7 peptide
substrate and reduced activity with EA2 substrates seven-fold.
The latter ¢nding is interesting as the EA2 substrate is one of
the best non-glycosylated peptide substrates identi¢ed for
both human and mouse GalNAc-T4 [5,6].
GalNAc-T7 showed a di¡erent pattern of activity with
these glycopeptides; it was inactive with the MUC1 derived
glycopeptide (GalNAc4TAP24), and weakly active with
Muc5AC and Muc7 glycoforms (Table 1). Similar to Gal-
NAc-T4, there was high activity with GalNAc-Muc2; how-
ever, while GalNAc-T7 showed high activity with the EA2
glycopeptide (13-fold enhancement), the activity of GalNAc-
T4 with this substrate was dramatically reduced. These results
demonstrate that the glycopeptide speci¢cities of GalNAc-T4
and -T7 di¡er and that the enzymes show distinct acceptor
peptide sequence speci¢cities. Detailed analysis of the sites of
GalNAc attachment to the GalNAc-peptide substrates (glyco-
sylated by GalNAc-T2) and products produced (by GalNAc-
T7) is required for further understanding of the substrate
speci¢city of GalNAc-T7. However, it was clear from the
mass spectrometric analysis of the substrates (apart from
TAP24 [5]) that these were not glycosylated in full at positions
used by GalNAc-T2; hence, clear assignment of site(s) used
subsequently by GalNAc-T7 are di⁄cult to de¢ne.
The activities of GalNAc-T4 and -T7 with the EA2 sub-
strate were studied in more detail (Fig. 3). GalNAc-EA2 gly-
copeptides with di¡erent densities of glycosylation were pre-
pared by in vitro glycosylation with GalNAc-T2. The activity
of GalNAc-T4 with the EA2 peptide is eliminated after incor-
poration of 1 mol GalNAc into the peptide. In contrast, the
activity with GalNAc-T7 is initiated with the 1 mol glycoform
of EA2 and further enhanced with higher density glycoforms
including the 3^4 mole glycoform. Analysis of the products of
terminal reactions with GalNAc-T7 of the three GalNAc-EA2
substrates (shown in Fig. 3) by mass spectrometry, showed
that GalNAc-T7 only incorporated 1 mol of GalNAc regard-
less of the degree of prior glycosylation (not shown). In par-
ticular, GalNAc-T7 increased the ratio of the 4 mol GalNAc
glycoform from the 3^4 mol substrate, and no evidence of
incorporation of a 5th mol of GalNAc was found. This sug-
gests that GalNAc-T7 utilizes one site in the EA2 peptide and
that this is a site poorly glycosylated by GalNAc-T2.
4. Discussion
The initiation step of mucin-type O-glycosylation is a com-
plex and regulated process carried out by multiple polypeptide
GalNAc-transferase isoforms [1]. The kinetic properties of
GalNAc-transferase isoforms are di¡erent and isoforms
clearly have di¡erent functions in terms of sites of attachment
in proteins [22]. Di¡erential expression of GalNAc-transferase
isoforms allows for cell speci¢c glycosylation patterns. Anal-
yses of the functions of recombinant transferases in in vitro
assays show that apart from qualitative di¡erences in acceptor
substrate speci¢cities, isoforms may also have common ac-
ceptor sites. The latter is frequently found with peptide sub-
strates derived from tandem repeat sequences of mucins,
which contain high density of potential Ser and Thr acceptor
sites often in clusters. Detailed analysis of the order in which
di¡erent GalNAc-transferase isoforms incorporate GalNAc
residues reveal striking di¡erences [9,10,23] and suggests that
the enzymes work in a coordinate fashion transferring to dif-
ferent sites. The ¢nding that the action of one GalNAc-trans-
ferase, GalNAc-T4, with unique acceptor sites in the MUC1
tandem repeat, is dependent on prior actions of other Gal-
NAc-transferases [5], further support that GalNAc-transfer-
ases function in a coordinate process. The present data extend
these observations and presents a novel human GalNAc-
transferase isoform, GalNAc-T7, that apparently show exclu-
sive acceptor substrate speci¢city for glycopeptides. In con-
trast to GalNAc-T4, the only substrates identi¢ed for Gal-
NAc-T7 were partially GalNAc glycosylated. Thus, the
kinetic properties of GalNAc-transferase isoforms with re-
spect to absolute and preferential speci¢cities for sequence
contexts of acceptor sites as well as speci¢cities for acceptor
sequences £anked by GalNAc glycosylated sites, allow for a
high degree of regulation in the process of initiation of
O-glycosylation. Di¡erential topography of GalNAc-transfer-
Fig. 2. Northern blot analysis of human tissues. Multiple human
Northern blot MTNIII (Clontech) was probed with 32P-labeled Gal-
NAc-T7.
Fig. 3. GalNAc-T4 and -T7 activities with EA2 peptide and Gal-
NAc glycosylated EA2 peptides. Designations: EA2, non-glycosyl-
ated peptide; EA2[GalNAc]1, EA2 glycosylated with GalNAc-T2 to
yield a glycoform with 1 mol GalNAc incorporated (mass spectral
analysis indicated that the majority of the substrate contained 1 mol
GalNAc with minor amounts of glycoforms with 2 and 3 mol of
GalNAc incorporated); EA2[GalNAc]3, EA2 glycosylated with Gal-
NAc-T2 to yield a glycoform with 3 mol GalNAc incorporated
(mass spectral analysis indicated that the majority of the substrate
contained 3 mol GalNAc with minor amounts of glycoforms with
2 and 4 mol of GalNAc incorporated); EA2[GalNAc]4, EA2 glyco-
sylated with GalNAc-T2 to yield a glycoform with 5 mol GalNAc
incorporated (mass spectral analysis indicated that the substrate
contained 3 and 4 mol GalNAc glycoforms).
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ase isoforms in the secretory pathway may also in£uence the
functions of GalNAc-transferase isoforms; however, analysis
of three isoforms by immunocytolocalization of tagged ex-
pression constructs suggests that these are found throughout
the Golgi stacks, albeit with some di¡erences in the pro¢le
[24].
It is clear that the primary sequence context of acceptor
substrates for O-glycosylation is the major determining factor
for the substrate speci¢cities of GalNAc-transferases [22].
GalNAc glycosylation of selected sites in a multiple acceptor
site peptide sequence may induce conformational changes fa-
voring the substrate speci¢cities of GalNAc-transferase iso-
forms. Several studies have demonstrated relative e¡ects, neg-
ative as well as positive, of adjacent and distant O-glycans on
the kinetics of subsequent in vitro O-glycosylation [23,25]. In
the case of GalNAc-T7 (and GalNAc-T4 with the MUC1
derived substrates), the e¡ect of preceding O-glycosylation is
an ultimate prerequisite for function. One hypothesis predicts
that these enzymes recognize a GalNAc residue in the context
of its attachment to the polypeptide backbone and that this
recognition event activates enzymatic function in an allosteric
manner. In this respect, Hazes [26] and Imberty et al. [27]
have identi¢ed a ricin lectin-like motif in the C-terminal re-
gion of GalNAc-transferases, but functionality for this do-
main has not been demonstrated. Hagen et al. [28] have re-
cently shown that the catalytic activity of GalNAc-T1 with an
unsubstituted peptide substrate is not signi¢cantly a¡ected by
detrimental mutations in the lectin domain. It remains open
whether this domain plays a role in the observed glycopeptide
speci¢cities of GalNAc-transferases like GalNAc-T4 and -T7.
Additional GalNAc-transferases with glycopeptide speci¢cities
functioning as follow-up enzymes may exist. The putative rat
GalNAc-T7 orthologue recently cloned was shown to exhibit
glycopeptide substrate speci¢city using the MUC5AC derived
peptide substrate glycosylated with GalNAc-T1 [29].
Interestingly, a comparative analysis of GalNAc-T4 and
-T7 activities with partially GalNAc-glycosylated peptides, de-
rived from mucin tandem repeats, showed that these have
di¡erent peptide substrate speci¢cities. GalNAc-T7 did not
show activity with the MUC1 derived glycopeptide, whereas
both enzymes showed high activity with the glycopeptide de-
rived from MUC2. Several non-glycosylated peptide sub-
strates have been identi¢ed for GalNAc-T4 including a se-
quence derived from rat submandibular mucin (EA2) [5,6].
The number and position of acceptor site(s) has not been
characterized but the activities of GalNAc-T4 and -T7 with
glycoforms of EA2 (Fig. 3) clearly demonstrate di¡erences in
activities. More detailed structural information is required on
the substrates used and products formed in those reactions.
In conclusion, the results indicate that several GalNAc-
transferases function in an independent fashion after the ac-
tion of other GalNAc-transferases. These ‘follow-up’ enzymes
have unique acceptor substrate speci¢cities, and they may play
a signi¢cant role in the glycosylation of tandem repeats of
mucins, which are characterized by high density clustering
of serine and threonine acceptor sites.
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